Dcpla-me
Dcpla-me has been studied in 1 paper since 2023: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 15, 2023: “PKCε activator protects hippocampal microvascular disruption and memory defect in 3×Tg-Alzheimer's disease mice with cerebral microinfarcts”.
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funder: National Institute on Aging
- Animals1
What did studies of dcpla-me find?
3Studies of dcpla-me measured 3 outcomes: apoptosis, hypoxia and HIF signaling and spatial memory defect.
Apoptosis
downin mice1
1 study
Apoptosis
downin mice1
Dcpla-me decreases apoptosis in 3×Tg mice with cerebral microinfarcts.
“DCPLA-ME prevented spatial memory defect; strong oxidative stress-related apoptosis”
Animalsin 3×Tg mice with cerebral microinfarctsmethyl-ester2 weeks
Frontiers in aging neuroscience
Hypoxia and HIF signaling
downin mice1
1 study
Hypoxia and HIF signaling
downin mice1
Dcpla-me decreases hypoxia and HIF signaling in 3×Tg mice with cerebral microinfarcts.
“DCPLA-ME prevented spatial memory defect; strong oxidative stress-related apoptosis; sustained hypoxia (by reducing HIF-1α and VEGF)”
Animalsin 3×Tg mice with cerebral microinfarctsmethyl-ester2 weeks
Frontiers in aging neuroscience
Spatial memory defect
downin mice1
1 study
Spatial memory defect
downin mice1
Dcpla-me prevents spatial memory defect in 3×Tg mice with cerebral microinfarcts.
“DCPLA-ME prevented spatial memory defect”
Animalsin 3×Tg mice with cerebral microinfarctsmethyl-ester2 weeks
Frontiers in aging neuroscience